A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Phase 2
258
about 2.6 years
18–65
7 sites in AR, CA, MD +2
What this study is about
Researchers are testing a treatment called emraclidine for people with schizophrenia. The trial will look at any side effects that may occur, how well the treatment works to reduce symptoms of schizophrenia, and how the drug moves through your body. Participants will receive either oral emraclidine or placebo for up to 42 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Emraclidine
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with Adverse Events (AEs), Part A Only- Accumulation ratio for Cmax (RacCmax) of Emraclidine, Part A Only- Terminal Phase Elimination Half-Life (t1/2) of Emraclidine, Part A Only-Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine, Part A Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine, Part A Only-Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364), Part A Only-Time to Cmax (Tmax) of Emraclidine, Part A Only-Time to Cmax (Tmax) of Metabolite (CV-0000364)
Secondary: Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score, Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score
Psychiatry / Mental Health